Acadia Pharmaceuticals reported $2.14M in Cost of Sales for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Acadia Pharmaceuticals ACAD:US USD 2.14M 531K
Alnylam Pharmaceuticals ALNY:US USD 41.12M 308K
Biogen BIIB:US USD 469.5M 14.5M
Biomarin Pharmaceutical BMRN:US USD 116.29M 6.84M
Bristol Myers Squibb BMY:US USD 2.52B 167M
Cara Therapeutics CARA:US USD 3.06M 3.06M
Corcept Therapeutics CORT:US USD 1.34M 23K
Eisai 4523:JP JPY 45.13B 2.27B
Eli Lilly And LLY:US USD 1.55B 31M
Intercept Pharmaceuticals ICPT:US USD 424K 115K
Intra Cellular Therapies ITCI:US USD 5.85M 1.2M
Johnson & Johnson JNJ:US USD 7.76B 29M
Moderna Inc MRNA:US USD 1.1B 281M
Neurocrine Biosciences NBIX:US USD 6.1M 1.3M
Pfizer PFE:US USD 9.82B 3.73B
Ptc Therapeutics PTCT:US USD 14.01M 4.37M
Sarepta Therapeutics SRPT:US USD 39.95M 2.16M
Seattle Genetics SGEN:US USD 108.12M 2.02M
Ultragenyx Pharmaceutical RARE:US USD 8.63M 361K
Vanda Pharmaceuticals VNDA:US USD 6.32M 261K
Vertex Pharmaceuticals VRTX:US USD 289.4M 27.6M
YTE INCY:US USD 49.28M 4.05M